IBRX270115C00010000
IBRX Jan 15 2027 10.00 Call
optionOPRA
EODOct 16, 2026
1.55USD-26.190%(-0.55)2,280Vol72,137OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
10
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.18 | -55.00% | 1,199 | 1,985 |
| Oct 30, 2026 | 10d | $0.32 | -54.29% | 35 | 768 |
| Nov 6, 2026 | 17d | $0.70 | -30.00% | 65 | 125 |
| Nov 13, 2026 | 24d | $0.70 | -40.68% | 9 | 38 |
| Nov 20, 2026 | 31d | $0.80 | -38.46% | 311 | 5,823 |
| Nov 27, 2026 | 38d | $1.00 | -31.03% | 3 | 86 |
| Dec 18, 2026 | 59d | $1.30 | +0.00% | 8 | 8 |
| Jan 15, 2027 | 87d | $1.55 | -26.19% | 2,280 | 72,137 |
| Mar 19, 2027 | 150d | $2.20 | -21.43% | 192 | 1,298 |
| Apr 16, 2027 | 178d | $2.10 | -27.84% | 8 | 120 |
| May 21, 2027 | 213d | $2.50 | -34.21% | 11 | 84 |
| Aug 20, 2027 | 304d | $3.48 | +2.35% | 8 | 364 |
| Nov 19, 2027 | 395d | $3.78 | -0.53% | 20 | 85 |
| Jan 21, 2028 | 458d | $3.20 | -14.44% | 677 | 10,691 |
| Mar 17, 2028 | 514d | $4.00 | +0.00% | 3 | 356 |
| Jan 19, 2029 | 822d | $4.50 | -4.46% | 6 | 2,594 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4 C | $5.70 | -6.10% | 1 | 5,546 | ITM |
| 4.5 C | $6.02 | +28.36% | 25 | 2,469 | ITM |
| 5 C | $4.40 | -16.98% | 41 | 26,601 | ITM |
| 5.5 C | $4.50 | -12.62% | 1 | 7,668 | ITM |
| 7.5 C | $2.65 | -11.67% | 315 | 21,039 | ITM |
| 9 C | $1.87 | -25.20% | 64 | 6,730 | OTM |
| 10 C | $1.55 | -26.19% | 2,280 | 72,137 | OTM |
| 11 C | $1.15 | -32.35% | 392 | 16,123 | OTM |
| 12 C | $1.00 | -31.03% | 717 | 10,602 | OTM |
| 13 C | $0.89 | -33.58% | 66 | 898 | OTM |
| 14 C | $1.00 | -16.67% | 10 | 3,110 | OTM |
| 15 C | $0.62 | -26.19% | 598 | 13,429 | OTM |
| 16 C | $0.52 | -36.59% | 1 | 2,413 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.